>

MEETINGS / EVENTS

RSS

May 05 - 07 2014, 12:00 AM - 12:00 AM

2014 ASA Legislative Conference

>

FDA MEDWATCH ALERTS

April 21, 2014

Lidocaine HCI Injection, USP, by Hospira: Recall - Visible Particulates

Summary:

Lidocaine HCI Injection USP by Hospira Recall Visible Particulates

April 18, 2014

Propofol Injectable Emulsion, USP by Hospira: Recall - Visible Particulates

Summary:

Propofol Injectable Emulsion USP by Hospira Recall Visible Particulates

April 18, 2014

FDA MedWatch - ARKON Anesthesia Delivery System with Version 2.0 Software by Spacelabs Healthcare: Class I Recall

Summary:

FDA MedWatch Class I Recall 4 18 14

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-14CE

... Read more »

Single Copies, Member Price: $360

Frequently Asked Questions About the “Company Model”

Wednesday, June 20, 2012

On June 1, 2012, the Department of Health and Human Services Office of Inspector General (HHS-OIG) issued an Advisory Opinion (No. 12-06) on a "company model" arrangement and expressed the view that it could violate the federal anti-kickback statute. 

In order to provide assistance to our members, ASA has created an FAQ document with answers to some of the most frequently asked questions regarding the “company model” and the Advisory Opinion.  The document will be updated as warranted.

Review ASA’s FAQs.

Review the HHS-OIG Advisory Opinion.

« Back to Washington Alerts